Literature DB >> 24438969

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

Sarah I Jawed1, Patricia L Myskowski1, Steven Horwitz2, Alison Moskowitz2, Christiane Querfeld3.   

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) comprise approximately 53% of cutaneous lymphomas. Both MF and SS may clinically and histologically mimic benign skin conditions, posing a diagnostic challenge to the dermatologist. Precise clinicopathologic correlation is necessary to support a diagnosis, especially in the early stages of disease. In addition to the identification of histopathologic criteria, ancillary studies, including the identification of CD4(+) T cells with aberrant immunophenotypes and T-cell receptor gene rearrangements within skin lesions and peripheral blood are used to support the diagnosis. Recent studies evaluating the pathogenesis of MF have found that the skin microenvironment, including immune cells, such as dendritic cells and reactive cytotoxic and regulatory T cells, plays a crucial supporting role in MF. The skin-homing ability of malignant T cells is the result of chemokines, cytokines, adhesion molecules, and defective apoptosis, and is believed to play a role in disease pathogenesis and progression. In addition, recent studies have also suggested that MF and SS arise from distinct memory T cell subsets and advanced/erythrodermic MF and SS may be distinguished by identification of certain molecules, including Programmed-Death-1.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  APC; CLA; CTCL; E-CTCL; EMF; GMF; HTLV-1; IL; ISCL; International Society for Cutaneous Lymphoma; LCT; MF; PD-1; Programmed-Death-1; SS; Sézary syndrome; T-cell receptor; TCR; Treg; antigen-presenting cell; biologic and molecular markers; clinical and diagnostic challenges; cutaneous T-cell lymphoma; cutaneous lymphocyte antigen; erythrodermic cutaneous T-cell lymphoma; erythrodermic mycosis fungoides; genetic aberrations; granulomatous mycosis fungoides; histopathology; human T-lymphotropic virus type 1; interleukin; large cell transformation; mycosis fungoides; mycosis fungoides subtypes; pathogenesis; prognostic value; regulatory T cells; skin homing features; transformed mycosis fungoides; tumor microenvironment

Mesh:

Substances:

Year:  2014        PMID: 24438969     DOI: 10.1016/j.jaad.2013.07.049

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  90 in total

1.  Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.

Authors:  Ivan V Litvinov; Michael T Tetzlaff; Philippe Thibault; Pamela Gangar; Linda Moreau; Andrew K Watters; Elena Netchiporouk; Kevin Pehr; Victor G Prieto; Elham Rahme; Nathalie Provost; Martin Gilbert; Denis Sasseville; Madeleine Duvic
Journal:  Oncoimmunology       Date:  2017-03-17       Impact factor: 8.110

2.  The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).

Authors:  Ivan V Litvinov; Elena Netchiporouk; Brendan Cordeiro; Marc-André Doré; Linda Moreau; Kevin Pehr; Martin Gilbert; Youwen Zhou; Denis Sasseville; Thomas S Kupper
Journal:  Clin Cancer Res       Date:  2015-03-16       Impact factor: 12.531

Review 3.  [Treatment of mycosis fungoides and Sézary syndrome].

Authors:  J P Nicolay; C Assaf
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

4.  Mycosis fungoides mimicking tinea pedis.

Authors:  Steven A Hanna; Mark G Kirchhof
Journal:  CMAJ       Date:  2016-10-31       Impact factor: 8.262

5.  Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma.

Authors:  Melania H Fanok; Amy Sun; Laura K Fogli; Vijay Narendran; Miriam Eckstein; Kasthuri Kannan; Igor Dolgalev; Charalampos Lazaris; Adriana Heguy; Mary E Laird; Mark S Sundrud; Cynthia Liu; Jeff Kutok; Rodrigo S Lacruz; Jo-Ann Latkowski; Iannis Aifantis; Niels Ødum; Kenneth B Hymes; Swati Goel; Sergei B Koralov
Journal:  J Invest Dermatol       Date:  2017-11-08       Impact factor: 8.551

6.  Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.

Authors:  Tzu-Pei Chang; Vladimir Poltoratsky; Ivana Vancurova
Journal:  J Immunol       Date:  2015-02-13       Impact factor: 5.422

7.  Rapamycin Suppresses Tumor Growth and Alters the Metabolic Phenotype in T-Cell Lymphoma.

Authors:  Wasakorn Kittipongdaja; Xuesong Wu; Justine Garner; Xiping Liu; Steven M Komas; Sam T Hwang; Stefan M Schieke
Journal:  J Invest Dermatol       Date:  2015-04-21       Impact factor: 8.551

8.  Scleromyxedematous Changes in a Patient With Long-Standing Mycosis Fungoides Who Progressed to Sézary Syndrome.

Authors:  Allen P Miraflor; Melissa P Pulitzer; Patricia L Myskowski; Shamir Geller
Journal:  Am J Dermatopathol       Date:  2019-11       Impact factor: 1.533

9.  [Management of cutaneous lymphomas].

Authors:  J P Nicolay; C-D Klemke
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

10.  Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy.

Authors:  Shamir Geller; Ken Pitter; Alison Moskowitz; Steven M Horwitz; Joachim Yahalom; Patricia L Myskowski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.